Charles Schwab Investment Management Inc. Acquires 57,677 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Charles Schwab Investment Management Inc. increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 5.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,134,651 shares of the medical research company's stock after acquiring an additional 57,677 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.88% of NeoGenomics worth $16,736,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NEO. Blue Trust Inc. boosted its position in shares of NeoGenomics by 107.2% in the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company's stock worth $32,000 after acquiring an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in NeoGenomics during the second quarter worth approximately $57,000. KBC Group NV boosted its holdings in shares of NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after purchasing an additional 1,127 shares during the last quarter. Banque Cantonale Vaudoise grew its stake in shares of NeoGenomics by 10.2% during the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company's stock valued at $244,000 after buying an additional 1,633 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of NeoGenomics during the 3rd quarter worth $312,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Stock Up 3.3 %

Shares of NeoGenomics stock traded up $0.57 during midday trading on Friday, hitting $17.76. The company's stock had a trading volume of 541,238 shares, compared to its average volume of 599,594. The firm has a market capitalization of $2.28 billion, a P/E ratio of -29.11 and a beta of 1.24. NeoGenomics, Inc. has a 1-year low of $12.77 and a 1-year high of $21.22. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $15.01.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. The company's revenue was up 10.5% compared to the same quarter last year. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NEO has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $19.00 price target on shares of NeoGenomics in a report on Wednesday, November 6th. Benchmark reissued a "buy" rating and set a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $20.25.

Insider Transactions at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by company insiders.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.